In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…
Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase
- Product
- AL001
- Milestone
- discontinuation
- Indication
- bipolar disorder
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The company received written FDA feedback on its proposed BD Phase II approach, paused the BD trial, and is preparing for a Type B meeting to revise the clinical development plan. MGH terminated the BD SOW, with a small refund, while the Healthy SOW and Healthy Patient Clinical Trial remain unaffected.
Market read
This is a development-plan and trial-execution reset for AL001 in bipolar disorder, driven by FDA feedback and followed by a BD trial pause and BD SOW termination.
What to watch
Healthy-subject Phase II work is completed and final results are expected in December 2026, which could partially offset BD-specific setbacks if data are strong.
Background
Alzamend Neuro’s AL001 program uses a Master Clinical Trial Agreement with Massachusetts General Hospital (MGH) covering multiple Phase II indications via separate statements of work.
Ticker impact
Alzamend Neuro paused its Phase II BD trial after FDA feedback questioned whether AL001 trials were adequate and well-controlled for effectiveness evidence.
Likely downside pressure as investors price in higher regulatory uncertainty and a longer path to an NDA after the BD Phase II pause and SOW termination.
The filing states the FDA did not support the proposed approach, the company paused the BD trial, and it plans to cease Phase II and move directly to Phase III, while BD SOW was terminated.
Market effects
Highlights FDA scrutiny on trial design adequacy for early-stage neuropsychiatric indications, potentially raising perceived regulatory bar for similar Phase II programs.
No direct regional market linkage beyond US biotech regulatory process.
US FDA feedback can affect global development timelines and investor sentiment for neuropsychiatric drug developers.
Counterpoint
The FDA feedback may still be constructive by steering the company toward a more supportable Phase III strategy, potentially improving the odds of an eventual NDA if the revised plan is executed well.
Key entities
- issuerAlzamend Neuro, Inc.
Company filing the 8-K; developing AL001 for multiple neuropsychiatric indications.
- drug_programAL001
Investigational asset whose BD Phase II development plan was challenged by FDA feedback.
- clinical_partnerThe General Hospital Corporation d/b/a Massachusetts General Hospital (MGH)
Clinical trial partner under the Master Clinical Trial Agreement; terminated the BD SOW after the trial pause.
- regulatorU.S. Food and Drug Administration (FDA)
Provided written feedback indicating the proposed trials may not be adequate and well-controlled to support effectiveness evidence.

